Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 6/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946840 | 0.82 | KDM4E (0.67) | KDM4EUBE2NALDH1A1ACLYHTR6 | |
| SCHEMBL14747171 | 0.82 | KDM4E (0.43) | KDM4EUBE2NALDH1A1ERN1PTPN1 | |
| SCHEMBL945672 | 0.80 | KDM4E (0.58) | KDM4EUBE2NHTR6 | |
| SCHEMBL4772872 | 0.79 | HTR6 (0.58) | KDM4EUBE2NHTR6 | |
| SCHEMBL27957970 | 0.78 | ACLY (0.36) | PTGER4ALDH1A1ACLYHTR6KCNH2 | |
| SCHEMBL8503228 | 0.78 | ACLY (0.45) | ACLYHTR6KCNH2 | |
| SCHEMBL948143 | 0.78 | HTR6 (0.55) | KDM4EUBE2NALDH1A1HTR6KCNH2 | |
| SCHEMBL949233 | 0.78 | KDM4E (0.52) | KDM4EUBE2NACLYHTR6 | |
| SCHEMBL4776515 | 0.78 | HTR6 (0.53) | KDM4EUBE2NALDH1A1HTR6 | |
| SCHEMBL1418230 | 0.78 | KDM4E (0.66) | KDM4EUBE2NALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664052-B1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20070185079-A1 | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| CN-1906169-A | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | US | disclosed |
| EP-1664052-A1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005016929-A1 | FUSED HETEROCYLCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | KDM4E 3332/4885UBE2N 3651/4885PTGER4 926/4885 |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | GLUL, RIMKLA, GGH | KDM4E 1267/4885UBE2N 962/4885PTGER4 2481/4885 |
| US-20070185079-A1 | Therapeutic agents I | HTT, GRIN2A, GRIN1 | KDM4E 2659/4885UBE2N 3184/4885PTGER4 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.